Synairgen: SNG001 Accelerates Viral Clearance In COPD Patients

Synairgen plc (SNG.L) reported positive data from additional assessments of lung sputum samples from its phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease patients with a confirmed respiratory viral infection. The company said this additional assessment supports continued and further investigation of SNG001 as a possible broad-spectrum antiviral.

Richard Marsden, CEO of Synairgen, said: "Our new data from COPD patients shows that SNG001 can accelerate viral clearance from the lung and builds on our existing data supporting SNG001's mechanism of action and our focus on severe viral lung infections."

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group. Kraft Heinz Foods Co. is recalling around 2,400 pounds of ready-to-eat or RTE ham and cheese loaf products citing possible cross-contamination with under-processed products, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. Foxconn, Apple Inc.'s key iPhone assembler, expects that its major plant in China, which is being hit hard by worker unrest following Covid-19 spread and related restrictions, would restart full production around late December to early January, Reuters reported citing a Foxconn source.
Follow RTT